Put lightly, it was less than a banner year for medical device and diagnostics companies looking to go public. Check out the report >>
Cancer Genetics will ramp up clinical trials plus expand its sales and marketing staff with an initial public offering the company envisions will haul in close to $49 million.
Australia seems to be an increasingly popular spot for foreign devicemakers to raise funds through initial public offerings and subsequently list on that country's exchange. Following in the footsteps of GI Dynamics, U.S.-based Osprey Medical has raised $20 million Australian in its IPO and plans to list on the Australian Securities Exchange.
Globus Medical made a splash Thursday by filing with the SEC to raise up to $100 million in an initial public offering.
Seattle's Atossa Genetics, which offers diagnostic tests to detect precursors to breast cancer, is planning an initial public offering of 1 million shares of its common stock. In a filing with the
Lexington, MA-based GI Dynamics has raised about $85 million from its Australian IPO. The company said it would list Sept. 7 in Sydney with a market value of AU$304 million ($324.6 million), The
France's Mauna Kea Technologies, which makes the world's smallest microscope used to examine the inside of the human body, is hoping to raise about $67.7 million from its initial public offering. As
Israel's Brainsway is dialing back its IPO expectations. It has filed more documents with the SEC saying it will offer about 1.8 million shares for between $10 and $12 per share. The filing comes
Rochester, NY-based Lucid, Inc. plans to sell up to $28.8 million of common stock in an IPO. The company says it will use the net proceeds to repay its debt and build its global research, sales,
Israel's Brainsway has filed its prospectus with the SEC to raise $30 million on NASDAQ. The company says in the filing that it will use approximately 70 to 75 percent of the net proceeds for